Basilea Pharmaceutica
Tracked across 3 events · 19 articles · First seen May 27, 2026 · Last active Jul 29, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Basilea Pharmaceutica received USD 13.3 million in funding from United States — Biomedical Advanced Research and Development Authority>>> to continue the development of its novel antibiotic, ceftibuten-ledaborbactam etzadroxil. This funding supports the advancement of its clinical phase 3 program, addressing a critical unmet need for oral treatment of complicated urinary tract infections.
May 27, 2026 · 7 articles
Business
Impact: Basilea received $30M milestone payment from BARDA, advancing its Phase 3 fosmanogepix program; stock rose 2.32%.
Jul 29, 2026 · 6 articles
Business
Impact: Basilea Pharmaceutica is the licensor of ZEVTERA to Innoviva.
Jun 01, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Basilea Pharmaceutica live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard